BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, Shi JJ, Zhang X, Jia XL, Dang SS. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study. World J Gastroenterol 2020; 26(13): 1525-1539 [PMID: 32308352 DOI: 10.3748/wjg.v26.i13.1525]
URL: https://www.wjgnet.com/2307-8960/full/v26/i13/1525.htm
Number Citing Articles
1
Bo Feng, Jia-Rui Zheng. Importance of quantitative HBsAg detection in whole course management of patients with chronic hepatitis BWorld Chinese Journal of Digestology 2022; 30(15): 655 doi: 10.11569/wcjd.v30.i15.655
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
2
Wencong Zhang, Mingyou Xing, Wenjin Sun, Jia Chen, Nana Xie, Yuan Cai, Ying Wang, Niuniu Li, Yujin Jiang, Fan Zhang, Yanfeng Wang, Qingjin Zeng, Yanhua Ji, Cheng Xu, Chunmei Jiang, Jianxin Song, Guojun Li. Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysisJournal of Viral Hepatitis 2023; 30(5): 427 doi: 10.1111/jvh.13792
3
Laura Iulia Grecu, Camelia Sultana, Mariana Pavel-Tanasa, Simona Maria Ruta, Mihaela Chivu-Economescu, Lilia Matei, Ramona Gabriela Ursu, Elena Iftimi, Luminita Smaranda Iancu. Non-Invasive Prediction Scores for Hepatitis B Virus- and Hepatitis D Virus-Infected Patients—A Cohort from the North-Eastern Part of RomaniaMicroorganisms 2023; 11(12): 2895 doi: 10.3390/microorganisms11122895
4
巧霞 陈. Research Progress of Pegylated Interferon Therapy for Chronic HBV InfectionAdvances in Clinical Medicine 2024; 14(03): 1605 doi: 10.12677/acm.2024.143884
5
Qian-Guo Mao, Hui-Qing Liang, Ya-Lin Yin, Jin-Mo Tang, Jia-En Yang, Chun-Cheng Wu, Yue Chen, Man-Ying Zhang, Yao-Yu Liu, Xiao-Ting Zheng, Lin-Yi Zhuang, Shao-Dong Chen. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis BClinics and Research in Hepatology and Gastroenterology 2022; 46(1): 101758 doi: 10.1016/j.clinre.2021.101758
6
Wen-Xin Wang, Rui Jia, Ying-Ying Gao, Jia-Ye Liu, Jun-Qing Luan, Fei Qiao, Li-Min Liu, Xiao-Ning Zhang, Fu-Sheng Wang, Junliang Fu. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patientsFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.894410
7
朝竟 温. Predictability and Durability of Functional Cure for Chronic Hepatitis BAdvances in Clinical Medicine 2023; 13(11): 18527 doi: 10.12677/ACM.2023.13112604
8
Fengping Wu, Rui Lu, Yixin Liu, Yikai Wang, Yan Tian, Yaping Li, Mei Li, Wenjun Wang, Xin Zhang, Xiaoli Jia, Shuangsuo Dang. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriersLiver International 2021; 41(9): 2032 doi: 10.1111/liv.14897
9
Xiaoan Yang, Ka Zhang, Qihuan Xu, Xin Shu, Zhishuo Mo, Dongying Xie, Zhiliang Gao, Hong Deng. Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAgFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.997608
10
Fengping Wu, Yikai Wang, Dandan Cui, Yan Tian, Rui Lu, Chenrui Liu, Mei Li, Yaping Li, Ning Gao, Zicheng Jiang, Xuemei Li, Song Zhai, Xin Zhang, Xiaoli Jia, Shuangsuo Dang. Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based RegimensJournal of Clinical Medicine 2023; 12(1): 361 doi: 10.3390/jcm12010361
11
Wen-Xin Wang, Rui Jia, Xue-Yuan Jin, Xiaoyan Li, Shuang-Nan Zhou, Xiao-Ning Zhang, Chun-Bao Zhou, Fu-Sheng Wang, Junliang Fu. Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patientsFrontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1121778
12
Huihui Lu, Wei Yi, Fangfang Sun, Zhan Zeng, Lu Zhang, Minghui Li, Yao Xie. Comprehensive investigation of HBV-related hepatocellular carcinoma and choice of anti-HBV therapyBiosafety and Health 2021; 3(4): 190 doi: 10.1016/j.bsheal.2021.05.001
13
Jun‐Hao Chu, Yan Huang, Dong‐Ying Xie, Hong Deng, Jia Wei, Yu‐Juan Guan, Guo‐Jun Li, Yi‐Lan Zeng, Jia‐Hong Yang, Xin‐Yue Chen, Jia Shang, Jia‐Bin Li, Na Gao, Zhi‐Liang Gao. Real‐world study on HBsAg loss of combination therapy in HBeAg‐negative chronic hepatitis B patientsJournal of Viral Hepatitis 2022; 29(9): 765 doi: 10.1111/jvh.13722
14
Chaojing Wen, Yixuan Wang, Haoyue Tian, Yu Lei, Zhiyi Wang, Dachuan Cai, Zhi Zhou, Xiaofeng Shi. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort studyFrontiers in Cellular and Infection Microbiology 2024; 13 doi: 10.3389/fcimb.2023.1332232
15
Shaowen Jiang, Simin Guo, Yan Huang, Yalin Yin, Jingwen Feng, Huijuan Zhou, Qing Guo, Weijing Wang, Haiguang Xin, Qing Xie. Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-α: a systematic review and meta-analysisHepatology International 2024;  doi: 10.1007/s12072-024-10648-8
16
Jun Chen, Min Qi, Xue-Gong Fan, Xing-Wang Hu, Cheng-Jin Liao, Li-Yuan Long, Xiao-Ting Zhao, Min Tan, Hai-Fu Li, Ruo-Chan Chen, Ze-Bing Huang, Yan Huang. Efficacy of Peginterferon alfa-2b in Nucleoside Analogue Experienced Patients with Negative HBeAg and Low HBsAg: A Non-Randomized Clinical TrialInfectious Diseases and Therapy 2021; 10(4): 2259 doi: 10.1007/s40121-021-00497-5
17
Shu Zhu, Lina Wu, Yongyu Mei, Zhihua Liu, Luping Lin, Jing Yuan, Jianguo Li, Xuejun Li, Liang Peng. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocolBMJ Open 2021; 11(10): e049104 doi: 10.1136/bmjopen-2021-049104
18
Hong Li, Shan Liang, Lili Liu, Daqiong Zhou, Yali Liu, Yang Zhang, Xinyue Chen, Jing Zhang, Zhenhuan Cao. Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferonFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1091786
19
Ya-Ping Li, Chen-Rui Liu, Miao Hao, Rui Lu, Shuang-Suo Dang. Clinical cure of hepatitis B: Delight and anticipationWorld Chinese Journal of Digestology 2023; 31(20): 837 doi: 10.11569/wcjd.v31.i20.837
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
20
Shima Mimura, Koji Fujita, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Joji Tani, Asahiro Morishita, Masafumi Ono, Takashi Himoto, Tsutomu Masaki. Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatmentExperimental and Therapeutic Medicine 2023; 26(6) doi: 10.3892/etm.2023.12286
21
Xiongyue Cao, Qiankun Hu, Wei Xu, Qiang Li, Jiming Zhang, Liang Chen, Yuxian Huang, Xun Qi. Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon‐alfaJournal of Viral Hepatitis 2023; 30(4): 310 doi: 10.1111/jvh.13787
22
Mei-Juan Peng, Xiao-Qing Guo, Wei-Lu Zhang, Jing Chen, Wen Kang, Xiao-Fei Yang, Ying Guo, Ye Zhang. Effect of pegylated interferon-α2b add-on therapy on renal function in chronic hepatitis B patients: A real-world experienceFrontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.980250